Prakt. lékáren. 2018; 14(4): 156-160 | DOI: 10.36290/lek.2018.030

Chronic obstructive pulmonary disease

Hana Kotolová, Tomáš Hammer
Ústav humánní farmakologie a toxikologie
Farmaceutická fakulta
Veterinární a farmaceutická univerzita Brno

Chronic obstructive pulmonary disease (COPD) is a serious progressive non-infectious inflammatory disease of the lower airwayswith increasing prevalence. This disease is characterized by bronchial obstruction, dyspnea and leads to a decrease in qualityof life. In recent years there have been changes in COPD diagnosis, but prevention and bronchodilatory drugs remain the basisfor therapy. The aim of this article is to summarize the pharmacological possibilities of COPD treatment with regard to the latesttrends and recommendations in this field.

Keywords: chronic obstructive pulmonary disease, global strategy, targeted treatment

Published: December 15, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kotolová H, Hammer T. Chronic obstructive pulmonary disease. Praktické lékárenství. 2018;14(4):156-160. doi: 10.36290/lek.2018.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kašák V. Farmakoterapie stabilizované chronické obstrukční plicní nemoci v České republice. Klinická farmakologie a farmacie. 2006, 20: 90-96.
    2. Rang H, Ritter J, Flower R, et al. Rang and Dale's pharmacology. 8th ed. Edinburgh etc.: Elsevier, Churchill Livingstone, 2016: 354-355.
    3. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Dostupné z: http://www.goldcopd.org
    4. Doporučený postup pro diagnostiku a léčbu exacerbace CHOPN (aktualizace 2016). Dostupné z: http://www.pneumologie.cz
    5. Vondra V. Těžká stadia chronické obstrukční plicní nemoci (CHOPN). Interní Med. 2007; 9(10): 424-428.
    6. Kašák V. Indacaterol-první inhalační ?2-agonista s ultra-dlouhodobým účinkem (ultra-LABA) pro léčbu CHOPN. Farmakoterapie, 2010, 6.1: 40-49.
    7. Domingo Ch. Ultra-LAMA, ultra-LABA, ultra-inhaled steroids? The future has landed. Archivos de Bronconeumología (English Edition), 2013, 49.4: 131-134. Go to original source...
    8. Niewoehner DE, Erbland ML, Deupree RH, et al.Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-1947. Go to original source... Go to PubMed...
    9. Pandya D, Puttanna A, Balagopal V. Suppl 1: M2: Systemic Effects of Inhaled Corticosteroids: An Overview. The open respiratory medicine journal, 2014, 8: 59. Go to original source... Go to PubMed...
    10. Cazzola M, Rogliani P, Calzetta L, et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14.5: 552-563. Go to original source... Go to PubMed...
    11. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. British Journal of Pharmacology. 2011; 163(1): 53-67. Go to original source... Go to PubMed...
    12. Vondra V. Roflumilast (Daxas) - nový lék v léčbě chronické obstrukční plicní nemoci. Praktické lékárenství, 2012, 8.1: 7-10.
    13. Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005; 172: 848-853. Go to original source... Go to PubMed...
    14. Martinez J, et al. Effect Of Roflumilast On Exacerbations In Patients With Severe COPD And A History Of Hospitalization Receiving Inhaled Combination Therapy: A Pooled Analysis Of Two Randomized Phase 4 Studies. C49. COPD: TREATMENT. American Thoracic Society, 2017. p. A5724-A5724.
    15. Cazzola M, Rogliani P, Calzetta L, et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD 2017; 14 (5): 552-563. Go to original source... Go to PubMed...
    16. Juergens U. Anti-inflammatory Properties of the Monoterpene 1.8-cineole: Current Evidence for Co-medication in Inflammatory Airway Diseases, Drug Research 2014 64 (12): 1-9. Go to original source... Go to PubMed...
    17. Singh D, Corradi M, Spinola M, et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J Chron Obstruct Pulmon, DiS. 2017; 12: 2917-2928. Go to original source... Go to PubMed...
    18. MV-AISLP pro Windows, verze 4.2018

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.